Replies to post #205515 on Biotech Values

[jbog]

Their U.S. Viekira Plan has been disastrous. I'm not sure if it's broken out but it seems that Merck's Zepatier could be outpacing it already.

[DewDiligence]

Viekira* Sales by Calendar Quarter ($ M)

  
          ---TOTAL--  ----US----  ---Ex-US-- 
 Quarter  Sales QoQ%  Sales QoQ%  Sales QoQ% 
    
   4Q16     311 -18%     54 -29%    257 -15% 
   3Q16     378 -10%     76 -13%    302  -9% 
   2Q16     419  +1%     87 -30%    332 +15% 
   1Q16     414 -26%    125 -37%    289 -19% 
   4Q15     554 +18%    197 -19%    357 +57% 
   3Q15     469 +21%    242  +7%    227 +44% 
   2Q15     385 +67%    227 +64%    158 +70% 
   1Q15     231  --     138  --      93  --

*Includes Viekira Pak, Technivie and Viekirax.